A mapping of patient characteristics that could help explain heterogeneity in treatment effects, collected by Case Report Forms (CRFs) in clinical trials for chronic conditions

A mapping of patient characteristics that could help explain heterogeneity in treatment effects, collected by Case Report Forms (CRFs) in clinical trials for chronic conditions

Background: Chronic health conditions are becoming more common in wealthy countries, affecting about 40% of adults. Such conditions put considerable strain on healthcare systems and patients. Typically, treatments for these conditions are based on what works on average in clinical trials. However, these averages often hide the fact that different patients respond differently to the same treatment. Despite this, we don't know enough about how clinical trials collect and use information about various patient characteristics that could explain these differences in treatment response.Objective: This study aims to find out what information is collected about a wide range of patient characteristics, including biological, clinical, psychosocial, and contextual factors, in clinical trials for chronic conditions that have been made available via the Clinical Study Data Request (CSDR) platform. We aim to identify what types of information these trials gather, how they measure this information, and whether this information is later presented as part of the trials' results reporting.Method: We will review the case report forms (CRFs) for a random sample of clinical trials available via the Clinical Study Data Request (CSDR) platform. We will examine what patient characteristics the CRFs collect, and categorize these thematically. We will also look at the measurement tools used to gather these data and check if and how this information is presented in the trials' results reporting.Impact: This study will shed light on the types of biological, clinical, and psychosocial patient characteristics collected by clinical trials available on the CSDR to understand what variables are available to examine why different patients respond differently to the same treatment. By identifying gaps in data collection and reporting, our findings could help improve the design of future trials and lead to more effective, personalized approaches to treating chronic conditions.

[{ "PostingID": 3956, "Title": "NOVARTIS-CAIN457A2302", "Description": "A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 3957, "Title": "NOVARTIS-CAIN457A2303", "Description": "A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 4045, "Title": "NOVARTIS-CQAB149B2311", "Description": "A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 4046, "Title": "NOVARTIS-CQVA149A2305", "Description": "A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control." },{ "PostingID": 4048, "Title": "NOVARTIS-CNVA237A2310", "Description": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD" },{ "PostingID": 4062, "Title": "NOVARTIS-CLCZ696B2314", "Description": "A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction" },{ "PostingID": 4069, "Title": "NOVARTIS-CAIN457A2307", "Description": "A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in patients with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)" },{ "PostingID": 4071, "Title": "NOVARTIS-CAIN457A2309", "Description": "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis" },{ "PostingID": 4082, "Title": "NOVARTIS-CVAL489E0108", "Description": "Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction" },{ "PostingID": 4083, "Title": "NOVARTIS-CCIB002I2301", "Description": "A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension" },{ "PostingID": 4084, "Title": "NOVARTIS-CFTY720D2301", "Description": "A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis" },{ "PostingID": 4086, "Title": "NOVARTIS-CENA713D1301", "Description": "A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)" },{ "PostingID": 4140, "Title": "NOVARTIS-CRAD001B253", "Description": "Two-year randomized, multi-center, doubleblind, double-dummy study of the efficacy and safety of everolimus versus azathioprine (AZA) as part of a triple immunosuppressive therapy regimen in de novo heart transplant
recipients." },{ "PostingID": 4141, "Title": "NOVARTIS-CRAD001H2304", "Description": "A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients" },{ "PostingID": 4163, "Title": "NOVARTIS-VEG110727", "Description": "A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy" },{ "PostingID": 4180, "Title": "NOVARTIS-CENA713B2311", "Description": "A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia" },{ "PostingID": 4191, "Title": "NOVARTIS-CZOL446H2301E1", "Description": "A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D" },{ "PostingID": 4192, "Title": "NOVARTIS-CZOL446H2301E2", "Description": "A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis" },{ "PostingID": 4195, "Title": "NOVARTIS-CZOL446M2309", "Description": "A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men" },{ "PostingID": 4204, "Title": "NOVARTIS-EGF102988", "Description": "A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)" },{ "PostingID": 4594, "Title": "NOVARTIS-CFTY720D2306", "Description": "A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis" },{ "PostingID": 4595, "Title": "NOVARTIS-CQVA149A2318", "Description": "A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME)." },{ "PostingID": 4688, "Title": "NOVARTIS-CENA713D2320", "Description": "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease" },{ "PostingID": 4689, "Title": "NOVARTIS-CENA713D2340", "Description": "A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase" },{ "PostingID": 4749, "Title": "NOVARTIS-CENA713DUS44", "Description": "A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44" },{ "PostingID": 4753, "Title": "NOVARTIS-CZOL446N2312", "Description": "A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia" },{ "PostingID": 14567, "Title": "NOVARTIS-CFEM345D2411", "Description": "Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer" },{ "PostingID": 16128, "Title": "NOVARTIS-CLAP016A2308", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer" },{ "PostingID": 16131, "Title": "NOVARTIS-CQVA149A2336", "Description": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation." },{ "PostingID": 16132, "Title": "NOVARTIS-CQVA149A2337", "Description": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation" },{ "PostingID": 16133, "Title": "NOVARTIS-CQVA149A2304", "Description": "A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 16135, "Title": "NOVARTIS-CQVA149A2307", "Description": "A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 16153, "Title": "NOVARTIS-CZOL446GDE19", "Description": "Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)" },{ "PostingID": 16159, "Title": "NOVARTIS-CRAD001Y2301", "Description": "A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole" },{ "PostingID": 19614, "Title": "NOVARTIS-CRAD001J2301", "Description": "A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer" },{ "PostingID": 19615, "Title": "NOVARTIS-CRAD001W2301", "Description": "A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer" },{ "PostingID": 19686, "Title": "NOVARTIS-CRAD001AUS92", "Description": "A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients" },{ "PostingID": 19688, "Title": "NOVARTIS-CAIN457F2336", "Description": "A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active psoriatic arthritis (FUTURE 4)" },{ "PostingID": 19790, "Title": "NOVARTIS-EGF105485", "Description": "A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer" },{ "PostingID": 19847, "Title": "NOVARTIS-CRAD001A2433", "Description": "A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation" },{ "PostingID": 19907, "Title": "NOVARTIS-CQTI571A2301", "Description": "A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)" },{ "PostingID": 19908, "Title": "NOVARTIS-CFEM345DDE09", "Description": "An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer" },{ "PostingID": 19909, "Title": "NOVARTIS-CZOL446 0011E1", "Description": "Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer" },{ "PostingID": 19986, "Title": "NOVARTIS-CACZ885N2301", "Description": "A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs" },{ "PostingID": 19987, "Title": "NOVARTIS-CNVA237A2319", "Description": "A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation" },{ "PostingID": 20037, "Title": "NOVARTIS-CRAD001HDE10", "Description": "Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients" },{ "PostingID": 20264, "Title": "NOVARTIS-CAIN457A2317", "Description": "A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLEAR)" },{ "PostingID": 20265, "Title": "NOVARTIS-CAIN457A2326", "Description": "A 52-week, randomized, double-blind study of secukinumab (300 mg) compared to ustekinumab in subjects with moderate to severe plaque psoriasis" },{ "PostingID": 20266, "Title": "NOVARTIS-CAIN457A2312", "Description": "A randomized, double-blind, placebo-controlled, multicenter study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe palmoplantar psoriasis" },{ "PostingID": 20267, "Title": "NOVARTIS-CAIN457A2313", "Description": "A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe nail psoriasis" },{ "PostingID": 20355, "Title": "NOVARTIS-CQVM149B2303", "Description": "A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma" },{ "PostingID": 20356, "Title": "NOVARTIS-CQVM149B2301", "Description": "A multi-center, randomized, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma." },{ "PostingID": 20357, "Title": "NOVARTIS-CFOR258D2416", "Description": "A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma." },{ "PostingID": 20574, "Title": "NOVARTIS-CDRB436B2302", "Description": "A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma" },{ "PostingID": 20606, "Title": "NOVARTIS-CINC424A2352", "Description": "A randomized study of the JAK inhibitor INC424 tablets compared to best available therapy in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)" },{ "PostingID": 20608, "Title": "NOVARTIS-CAMN107ECN02", "Description": "ENESTChina: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in Chinese adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)" },{ "PostingID": 20609, "Title": "NOVARTIS-CAMN107A2303", "Description": "A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph positive) chronic myelogenous leukemia in chronic phase (CML-CP)." },{ "PostingID": 20621, "Title": "NOVARTIS-CQAW039A2316", "Description": "A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma" },{ "PostingID": 20622, "Title": "NOVARTIS-CAIN457F2302/E1", "Description": "A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF¿ agents (CAIN457F2302) and a three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis (CAIN457F2302E1)" },{ "PostingID": 20760, "Title": "NOVARTIS-CIGE025AFR05", "Description": "A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy" },{ "PostingID": 20761, "Title": "NOVARTIS-CIGE025A2313", "Description": "A 24-week, Phase III randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of Xolair® (omalizumab) in patients with moderate to severe persistent allergic asthma who remain not adequately controlled despite GINA (2009) Step 4 therapy" },{ "PostingID": 20818, "Title": "NOVARTIS-CRAD001O2301", "Description": "A randomized Phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment¿ the EVOLVE-1 Study" },{ "PostingID": 20836, "Title": "NOVARTIS-RTH258-C002", "Description": "A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration" },{ "PostingID": 20838, "Title": "NOVARTIS-CQAW039A2307", "Description": "A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma." },{ "PostingID": 20839, "Title": "NOVARTIS-CQAW039A2314", "Description": "A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe Asthma." },{ "PostingID": 20857, "Title": "NOVARTIS-CRAD001C2325", "Description": "A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or San-dostatin LAR® Depot and placebo" },{ "PostingID": 20858, "Title": "NOVARTIS-CRAD001C2324", "Description": "A randomized double-blind phase III study of everolimus 10 mg/d plus best supportive care (BSC) versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuro-endocrine tumor (NET)" },{ "PostingID": 20877, "Title": "NOVARTIS-CAIN457F2366", "Description": "A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of secukinumab monotherapy compared with adalimumab monotherapy in patients with active psoriatic arthritis" },{ "PostingID": 20880, "Title": "NOVARTIS-CTMT212A2301 (GSK-114267)", "Description": "A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma" },{ "PostingID": 20882, "Title": "NOVARTIS-CAIN457AUS01", "Description": "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab 300 mg as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis" },{ "PostingID": 20884, "Title": "NOVARTIS-CLAF237A23135", "Description": "A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus" },{ "PostingID": 20885, "Title": "NOVARTIS-CLAF237A23118", "Description": "A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure" },{ "PostingID": 20888, "Title": "NOVARTIS-CLAF237A23137", "Description": "A multi-center, randomized, double-blind, clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency" },{ "PostingID": 20889, "Title": "NOVARTIS-CLAF237A2398", "Description": "A Multi-center, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with Type 2 Diabetes" },{ "PostingID": 20891, "Title": "NOVARTIS-CLAF237A2308", "Description": "A multicenter, randomized, double-blind, active controlled study to compare the long-term effect of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy" },{ "PostingID": 20892, "Title": "NOVARTIS-CLAF237A2310", "Description": "A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type 2 diabetes" },{ "PostingID": 20895, "Title": "NOVARTIS-CLAF237A2309", "Description": "A multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetes." },{ "PostingID": 21053, "Title": "NOVARTIS-BRF113683 / CDRB436A2301", "Description": "A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma" },{ "PostingID": 21063, "Title": "NOVARTIS-113387/CPZP034D2301", "Description": "A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy" }]